Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis

X. Zhang(Bristol-Myers Squibb (United States)), E. Scott Priestley(Bristol-Myers Squibb (United States)), Dyamanna Doddalingappa(Bristol-Myers Squibb (India)), R. Michael Lawrence(Bristol-Myers Squibb (United States)), Pancras C. Wong(Bristol-Myers Squibb (United States)), Samuel K. Reznik(Bristol-Myers Squibb (United States)), Jeremy M. Richter(Bristol-Myers Squibb (Germany)), Ulaganathan Sankar(Bristol-Myers Squibb (India)), Victor R. Guarino(Bristol-Myers Squibb (United States)), Shana Posy(Bristol-Myers Squibb (United States)), Chi Shing Sum(Bristol-Myers Squibb (United States)), Jing Yang(Bristol-Myers Squibb (United States)), Joyce Dickey(Bristol-Myers Squibb (United States)), Richard Rampulla(Bristol-Myers Squibb (United States)), Sylwia Stachura(Bristol-Myers Squibb (United States)), Ji Hua(Bristol-Myers Squibb (United States)), Wen Jiang(Bristol-Myers Squibb (United States)), David A. Gordon(Bristol-Myers Squibb (United States)), David Harden(Bristol-Myers Squibb (United States)), William A. Schumacher(Bristol-Myers Squibb (United States)), Jeffrey S. Bostwick(Bristol-Myers Squibb (United States)), Ruth R. Wexler(DuPont (United States)), Jay Bates(Bristol-Myers Squibb (United States)), Sarah E. Malmstrom(Bristol-Myers Squibb (United States))
Journal of Medicinal Chemistry
February 22, 2024
Cited by 12


Related Papers